The lure of ‘miracle’ medication to reduce weight: the rebound impact is quicker than with standard diets | Health and well-being | EUROtoday

The historical past of the battle towards weight problems has modified radically since, lower than a decade in the past, GLP-1 therapies appeared, with medicines akin to Ozempic, Wegovy or Mounjaro. The medication are so common that they’ve reworked the determine of quite a few celebritieshave taken the black market by storm and even the World Health Organization has acknowledged them as important to humanity and believes they need to be “universally accessible.” But actuality is at all times extra difficult than the miracle narrative. An exhaustive evaluation revealed at this time Wednesday within the journal The BMJ opinions 37 research with greater than 9,300 contributors, and definitively punctures the balloon of hope of shedding weight with none effort. The discovering is overwhelming: individuals who cease taking these medicines regain the misplaced weight in lower than 1.7 years, at a mean charge of 0.4 kilograms per thirty days. Furthermore, this restoration is considerably quicker than that noticed after abandoning standard weight loss plan and train applications, the place the return to preliminary weight takes virtually 4 years.

The evaluation of research revealed at this time exhibits that, within the first twelve months after stopping remedy, individuals regain a mean of 4.8 kilograms in the event that they used any remedy, 6 kilograms in the event that they used all incretin agonists, akin to Exenatide, and 9.9 kilograms in the event that they took the newer and simpler medication: semaglutide (akin to Ozempic or Wegovy) and tirzepatide (akin to Mounjaro).

Perhaps extra regarding than the burden achieve is the impact of stopping the medication on markers of cardiovascular and metabolic well being: The useful results on excessive ldl cholesterol, triglycerides, fasting glucose, and hypertension are reversed, and sufferers’ indicators return to the place they began in about 1.4 years.

Sam West, a researcher on the University of Oxford and lead creator of the evaluation, explains a key discovering to this newspaper: “The speed of weight regain depended mainly on how much weight had been lost. More weight loss equals faster weight regain. That’s why people regained weight faster after GLP-1 agonists: because they had lost more weight.”

In different phrases, a part of the distinction between regaining weight after utilizing medicines versus regaining weight after a weight loss plan is defined merely since you lose extra weight with the medication. But this doesn’t invalidate the central discovering: the restoration stays worryingly speedy.

The really problematic factor shouldn’t be solely that there’s weight regain and that the well being advantages are reversed. The reality is that, even controlling for the quantity of kilos misplaced, restoration is quicker after medicines than after behavioral interventions.

West highlights an necessary limitation: For the newer, extra highly effective medication — semaglutide and tirzepatide — follow-up information after stopping remedy is restricted to about 12 months. Recovery projections in two years are primarily based on extrapolations. “Only one of the 37 included studies provided two-year follow-up after stopping medication,” he notes. Still, the sample is constant throughout all research.

Adam Collins, professor of Nutrition on the University of Surrey, gives a proof that lots of the pharmaceutical corporations that manufacture these medication (and the personal clinics that supply them at exorbitant costs) don’t clarify to their potential sufferers: artificially offering ranges of GLP-1 a lot increased than regular for months could cause the physique to supply much less pure GLP-1 and be much less delicate to its results. “There is no problem while you take the drugs, but as soon as you withdraw this arrangement of GLP-1, appetite is no longer controlled and overeating becomes much more likely. Like any addiction, quitting cold turkey is a real challenge,” he tells the scientific portal SMC.

Back support

One of the surprises of the analysis is that behavioral support programs during drug treatment did not reduce the speed of subsequent recovery. West clarifies why: “It’s possible that because medication works to reduce hunger, it undermines the value of conscious diet and physical activity efforts. But we also need more data evaluating what types of behavioral supports might be effective during treatment.” And the medicine does the job so well that people never learn to control their own appetite. And when the medication wears off, they don’t have the tools to do it.

John Wilding, a professor at the University of Liverpool and co-author of several of the trials on these drugs, defends a more nuanced perspective. “Obesity is a chronic disease that usually relapses when treatment is stopped. We do not expect that interventions for other chronic diseases will continue to work when they are stopped. There is no scientific reason for obesity to be different,” he explains to the SMC.

However, unlike diabetes or hypertension, where patients know they need indefinite medication, the marketing narrative around these drugs has been that of a temporary solution; an intervention. Wilding adds a fact: “We know that people at high risk of cardiovascular disease are less likely to suffer an adverse event if they take GLP-1-based drugs long term.” The downside is that in nations just like the United States, roughly 50% of individuals abandon these medicines within the first 12 months. Due to price, unwanted side effects, or just tiredness of the injections.

Qi Sun, a professor at Harvard University, writes an editorial in the same issue of The BMJ, and is very direct in his conclusions: “Weight loss medicines shouldn’t be thought of magic bullets for treating weight problems. Healthy dietary and life-style practices ought to stay the idea of remedy, with medicines used as enhances, not substitutes.”

Naveed Sattar, Professor of Cardiometabolic Medicine at the University of Glasgow, offers a more optimistic perspective: “Continuous use of these medications for 3-4 years allows people to maintain a significantly lower weight than they would otherwise have, a benefit not usually seen with weight loss induced by lifestyle changes,” he tells SMC. But it recognizes that this requires continued access and affordable prices, something that is not guaranteed. West admits that a crucial limitation of this study is that it was done with clinical analysis: “The conditions in the trials are very different, and we really need real-world data to better understand the characteristics of the people who use the medication, the magnitude of weight loss, the dropout rates and the weight regain rates.”

In any case, the information signifies that there aren’t any miracles and {that a} nutritious diet and train stay very important to combating weight problems. Sun concludes: “Healthy dietary and lifestyle practices should remain the basis of obesity treatment and management, and effective public health measures, such as taxation on sugary drinks, clear food labeling, and subsidies for fresh fruits and vegetables, should be implemented to facilitate improved diet quality.”